Design Therapeutics, Inc. (DSGN) 10-Year Financial Performance & Capital Metrics

DSGN • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutDesign Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Show more

Revenue $0
EBITDA -$62M +20.4%
Net Income -$50M +25.8%
EPS (Diluted) -0.88 +26.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -19.08% +13.7%
ROIC -19.44% +6.5%
Debt/Equity 0.01 -12.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 92 (top 8%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-41.16%

EPS CAGR

10Y-

5Y-

3Y-

TTM-40%

ROCE

10Y Avg-28.29%

5Y Avg-28.29%

3Y Avg-22.78%

Latest-23.83%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	834	0	0	0	0	0
Revenue Growth %	-	-1%	-	-	-	-
Cost of Goods Sold+	1.65K	5K	0	466K	537K	596K
COGS % of Revenue	1.98%	-	-	-	-	-
Gross Profit+	-820	-5K	0	-466K	-537K	-596K
Gross Margin %	-0.98%	-	-	-	-	-
Gross Profit Growth %	-	-5.1%	1%	-	-0.15%	-0.11%
Operating Expenses+	1.91M	8.55M	35.83M	67.13M	77.65M	61.79M
OpEx % of Revenue	2287.77%	-	-	-	-	-
Selling, General & Admin	1.09M	2.5M	11.05M	18.98M	21.13M	18.03M
SG&A % of Revenue	1304.56%	-	-	-	-	-
Research & Development	1.65M	6.06M	24.78M	48.61M	57.06M	44.35M
R&D % of Revenue	1983.21%	-	-	-	-	-
Other Operating Expenses	-834K	0	0	-466K	-537K	-596K
Operating Income+	-1.91M	-8.56M	-35.83M	-67.59M	-78.19M	-62.38M
Operating Margin %	-2287.77%	-	-	-	-	-
Operating Income Growth %	-	-3.48%	-3.19%	-0.89%	-0.16%	0.2%
EBITDA+	0	-8.55M	-35.7M	-67.13M	-77.65M	-61.79M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-	-3.18%	-0.88%	-0.16%	0.2%
D&A (Non-Cash Add-back)	1.91M	5K	129K	466K	537K	596K
EBIT	-2.05M	-8.28M	-35.83M	-63.31M	-66.86M	-49.59M
Net Interest Income+	0	0	0	0	0	12.79M
Interest Income	0	0	0	0	0	12.79M
Interest Expense	0	0	0	0	0	0
Other Income/Expense	-139K	276K	298K	4.29M	11.33M	12.79M
Pretax Income+	-2.05M	-8.28M	-35.53M	-63.31M	-66.86M	-49.59M
Pretax Margin %	-2454.44%	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-2.05M	-8.28M	-35.53M	-63.31M	-66.86M	-49.59M
Net Margin %	-2454.44%	-	-	-	-	-
Net Income Growth %	-	-3.04%	-3.29%	-0.78%	-0.06%	0.26%
Net Income (Continuing)	-2.05M	-8.28M	-35.53M	-63.31M	-66.86M	-49.59M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.08	-0.30	-0.77	-1.14	-1.19	-0.88
EPS Growth %	-	-2.98%	-1.57%	-0.48%	-0.04%	0.26%
EPS (Basic)	-0.08	-0.30	-0.77	-1.14	-1.19	-0.88
Diluted Shares Outstanding	27.19M	27.19M	45.94M	55.71M	55.98M	56.59M
Basic Shares Outstanding	27.19M	27.19M	45.94M	55.71M	55.98M	56.59M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	90K	36.23M	385.44M	335.12M	284.58M	248.04M
Cash & Short-Term Investments	77K	36.09M	384.06M	330.39M	281.8M	245.48M
Cash Only	77K	2.38M	298.57M	26.5M	21.2M	22.56M
Short-Term Investments	0	33.71M	85.5M	303.89M	260.6M	222.91M
Accounts Receivable	0	10K	110K	1.11M	1.43M	1.26M
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	8K	25K	0	0	0	0
Total Non-Current Assets+	0	283K	5.12M	6.02M	5.06M	4.05M
Property, Plant & Equipment	0	71K	5.12M	5.56M	4.63M	3.63M
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	212K	0	459K	430K	427K
Total Assets+	90K	36.52M	390.56M	341.14M	289.64M	252.09M
Asset Turnover	0.01x	-	-	-	-	-
Asset Growth %	-	404.73%	9.7%	-0.13%	-0.15%	-0.13%
Total Current Liabilities+	3.73M	2.33M	5.28M	10.78M	9.62M	8.46M
Accounts Payable	2.48M	1.4M	1.62M	3.02M	1.94M	2.19M
Days Payables Outstanding	547.06K	102.13K	-	2.37K	1.32K	1.34K
Short-Term Debt	695K	0	0	0	0	0
Deferred Revenue (Current)	201K	0	0	0	0	0
Other Current Liabilities	112K	565K	2.15M	3.54M	4.03M	0
Current Ratio	0.02x	15.55x	72.96x	31.10x	29.58x	29.31x
Quick Ratio	0.02x	15.55x	72.96x	31.10x	29.58x	29.31x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	1K	45.5M	3.14M	3.05M	2.33M	1.53M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	3.14M	3.05M	2.33M	1.53M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	1K	45.5M	0	0	0	0
Total Liabilities	3.73M	47.83M	8.43M	13.83M	11.96M	10M
Total Debt+	695K	0	3.63M	3.69M	3.05M	2.33M
Net Debt	618K	-2.38M	-294.94M	-22.81M	-18.15M	-20.23M
Debt / Equity	-	-	0.01x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-
Total Equity+	-3.64M	-11.31M	382.13M	327.31M	277.69M	242.1M
Equity Growth %	-	-2.11%	34.77%	-0.14%	-0.15%	-0.13%
Book Value per Share	-0.13	-0.42	8.32	5.88	4.96	4.28
Total Shareholders' Equity	-3.64M	-11.31M	382.13M	327.31M	277.69M	242.1M
Common Stock	1K	1K	6K	6K	6K	6K
Retained Earnings	-3.64M	-11.92M	-47.46M	-110.76M	-177.63M	-227.21M
Treasury Stock	0	-451K	0	0	0	0
Accumulated OCI	0	156K	-244K	-3.36M	62K	475K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-139K	-8.67M	-29.38M	-51.32M	-58.56M	-43.1M
Operating CF Margin %	-166.67%	-	-	-	-	-
Operating CF Growth %	-	-61.37%	-2.39%	-0.75%	-0.14%	0.26%
Net Income	-2.05M	-8.28M	-35.53M	-63.31M	-66.86M	-49.59M
Depreciation & Amortization	0	5K	129K	406K	537K	-5.6M
Stock-Based Compensation	0	450K	4.69M	10.93M	13.09M	13.07M
Deferred Taxes	0	0	-77K	0	0	0
Other Non-Cash Items	95K	-33K	19K	-1.33M	-6.05M	6K
Working Capital Changes	1.81M	-811K	1.4M	1.99M	728K	-993K
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	0	-413K	2.41M	5.38M	-1.25M	-1.22M
Cash from Investing+	0	-33.56M	-53.64M	-220.99M	52.54M	43.95M
Capital Expenditures	0	-76K	-1.54M	-918K	-256K	-340K
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	-52.11K	0	0	0
Cash from Financing+	196K	44.53M	379.21M	235K	724K	513K
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	1K	228K	-427K	0	0
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-139K	-8.74M	-30.91M	-52.23M	-58.82M	-43.45M
FCF Margin %	-166.67%	-	-	-	-	-
FCF Growth %	-	-61.91%	-2.54%	-0.69%	-0.13%	0.26%
FCF per Share	-0.01	-0.32	-0.67	-0.94	-1.05	-0.77
FCF Conversion (FCF/Net Income)	0.07x	1.05x	0.83x	0.81x	0.88x	0.87x
Interest Paid	0	24K	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-19.16%	-17.85%	-22.1%	-19.08%
Return on Invested Capital (ROIC)	-	-	-73.12%	-25.88%	-20.79%	-19.44%
Gross Margin	-98.32%	-	-	-	-	-
Net Margin	-245443.65%	-	-	-	-	-
Debt / Equity	-	-	0.01x	0.01x	0.01x	0.01x
FCF Conversion	0.07x	1.05x	0.83x	0.81x	0.88x	0.87x
Revenue Growth	-	-100%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Design Therapeutics, Inc. (DSGN) grew revenue by 0.0% over the past year. Growth has been modest.

Design Therapeutics, Inc. (DSGN) reported a net loss of $67.4M for fiscal year 2024.

Dividend & Returns

Design Therapeutics, Inc. (DSGN) has a return on equity (ROE) of -19.1%. Negative ROE indicates the company is unprofitable.

Design Therapeutics, Inc. (DSGN) had negative free cash flow of $52.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener